Tag: M.W:200-300

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.85275-45-2,tert-Butyl 3-hydroxypiperidine-1-carboxylate,as a common compound, the synthetic route is as follows.

Step 4. Preparation of tert-butyl 3-(tosyloxy)piperidine-1-carboxylate: To a solution of tert-butyl 3-hydroxypiperidine-1-carboxylate (1.05 g, 5.0 mmol) in pyridine (8 mL) is added TsCl (1.425 g, 7.5 mmol). The mixture is stirred at RT under N2 for two days. The mixture is concentrated and partitioned between 100 mL of EA and 100 mL of HCl (1 N) aqueous solution. The organic layer is separated from aqueous layer, washed with saturated NaHCO3 aqueous solution (100 mL ¡Á 2), brine (100 mL ¡Á 3) and dried over Na2SO4. The organic layer is concentrated to afford 1.1 g (60%) of tert-butyl 3-(tosyloxy)piperidine-1- carboxylate as a colorless oil.

85275-45-2, 85275-45-2 tert-Butyl 3-hydroxypiperidine-1-carboxylate 545699, apiperidines compound, is more and more widely used in various fields.

Reference£º
Patent; ACERTA PHARMA B.V.; HAMDY, Ahmed; ROTHBAUM, Wayne; IZUMI, Raquel; LANNUTTI, Brian; COVEY, Todd; ULRICH, Roger; JOHNSON, Dave; BARF, Tjeerd; KAPTEIN, Allard; (732 pag.)WO2016/24230; (2016); A1;,
Piperidine – Wikipedia
Piperidine | C5H11N – PubChem

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.184637-48-7,tert-Butyl 3-aminopiperidine-1-carboxylate,as a common compound, the synthetic route is as follows.

Example 6Step 1tert-Butyl 1-(7-(3,4-dimethoxyphenylamino)thiazolo[5,4-d]pyrimidin-5-yl)piperidin-3-ylcarbamate Procedure:To a stirred solution of tert-butyl 1-(7-(3,4-dimethoxyphenylamino)thiazolo[5,4-d]pyrimidin-5-yl)piperidin-3-ylcarbamate (140 mg, 0.433 mmol), tert-butyl piperidin-3-ylcarbamate (130 mg, 0.649 mmol), X-Phos (115 mg, 0.24 mmol) and Cs2CO3 (580 mg, 1.78 mmol) in 60 mL of dry dioxane was added Pd2(dba)3 (60 mg, 0.065 mmol) in one portion at room temperature under nitrogen. Then the reaction mixture was degassed with nitrogen for 15 minutes. After that, the mixture was stirred at 95¡ã C. under nitrogen for 24 hours. The solvent was evaporated and the residue was purified by silica gel chromatography (silica gel 200-300 mesh, petroleum ether:ethyl acetate=1:2) to give tert-butyl 1-(7-(3,4-dimethoxyphenylamino)thiazolo[5,4-d]pyrimidin-5-yl)piperidin-3-ylcarbamate (195 mg, 92.8percent) as a solid. LC-MS: 487.1 [M+H]+, tR=1.67 min., 184637-48-7

As the paragraph descriping shows that 184637-48-7 is playing an increasingly important role.

Reference£º
Patent; Hermann, Johannes Cornelius; Lowrie, JR., Lee Edwin; Lucas, Matthew C.; Luk, Kin-Chun Thomas; Padilla, Fernando; Wanner, Jutta; Xie, Wenwei; Zhang, Xiaohu; US2012/252777; (2012); A1;,
Piperidine – Wikipedia
Piperidine | C5H11N – PubChem

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.91419-52-2,1-Boc-4-Cyanopiperidine,as a common compound, the synthetic route is as follows.,91419-52-2

To a mixture of 4-cyano-piperidine-1-carboxylic acid tert-butyl ester (6.3 g, 30 mmol), K2C03 (4.2 g, 30 mmol) in H20 (50 mL) and EtOH (30 mL) was added hydroxylamine hydrogenchloride (4.17 g, 60 mmol). The mixture was heated under reflux overnight, cooled to room temperature and ethanol was removed in vacuo. The residue was extracted with EtOAc (300 mL). The organic layer was washed successively with H20 and brine. After drying (Na2 SO4), the solvent was removed to afford the desired product

91419-52-2 1-Boc-4-Cyanopiperidine 1514443, apiperidines compound, is more and more widely used in various fields.

Reference£º
Patent; CYMABAY THERAPEUTICS; MCWHERTER, Charles A.; (176 pag.)WO2018/26890; (2018); A1;,
Piperidine – Wikipedia
Piperidine | C5H11N – PubChem

142643-29-6, 3-(Boc-aminomethyl)piperidine is a piperidines compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

64a) {1-[2-(3-Chloro-6-methoxy-quinolin-4-yl)-2-hydroxy-ethyl]-piperidin-3-ylmethyl}-carbamic acid tert-butyl ester (enantiomer1)Epoxide (56f) (900 mg), 3-(N-Boc-aminomethyl)piperidine (819ing) i potassium carbonate (555 mg) and lithium perchlorate (405mg) were suspended in DMF (9 ml) and heated in the microwave for35 minutes at 130C. The mixture was concentrated, the residuedissolved in ethyl acetate and washed with water and brine. Theorganic layer was dried over magnesium sulfate, filtered andevaporated. The residue was purified by flash chromatography(silica gel, dichloromethane/methanol 97:3) to give the desiredproduct (1.6 g).MS (El): m/z: 450 [M+H]+, 142643-29-6

The synthetic route of 142643-29-6 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; MORPHOCHEM AKTIENGESELLSCHAFT FUeR KOMBINATORISCHE CHEMIE; WO2006/21448; (2006); A1;,
Piperidine – Wikipedia
Piperidine | C5H11N – PubChem

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.871022-62-7,tert-Butyl ((4-fluoropiperidin-4-yl)methyl)carbamate,as a common compound, the synthetic route is as follows.

[00344] Step a: A mixture of 3-((3-amino-2-chlorophenyl)thio)-6-chloropyrazin-2- amine (200 mg, 0.696 mmol) and tert-butyl ((4-fluoropiperidin-4-yl)methyl)carbamate (243 mg, 1.045 mmol), and DIPEA (0.6 mL, 3.48 mmol) in NMP (2 mL) was stirred for 16 h at 150 C. After cooling to RT, the reaction mixture was poured into a separation funnel containing brine and it was extracted with EtOAc (3 x 5 mL). The combined organic phases were dried over MgS04, filtered and the volatiles were removed under reduced pressure. The resulting residue was purified by silica chromatography (0 to 10% gradient of MeOH DCM) to give tert-butyl ((l-(6-amino-5- ((3-amino-2-chlorophenyl)thio)pyrazin-2-yl)-4-fluoropiperidin-4-yl)methyl)carbamate (285 mg, 0.590 mmol). MS m/z 483.1 (M+H)+.

871022-62-7, As the paragraph descriping shows that 871022-62-7 is playing an increasingly important role.

Reference£º
Patent; NOVARTIS AG; CHEN, Zhuoliang; DORE, Michael; FORTANET, Jorge Garcia; KARKI, Rajesh; KATO, Mitsunori; LAMARCHE, Matthew J.; PEREZ, Lawrence Blas; WILLIAMS, Sarah; SENDZIK, Martin; WO2015/107494; (2015); A1;,
Piperidine – Wikipedia
Piperidine | C5H11N – PubChem

1016258-66-4, 1-tert-Butyl 4-ethyl 4-cyanopiperidine-1,4-dicarboxylate is a piperidines compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

EXAMPLE 26N-((lH-Indol-2-yl)methv?-4-(aminomethv?-l-(7H-pyrrolor2.3-d1pyrimidin-4- yl)piperidine-4-carboxamide26A. 1 -(tert-Butoxycarbonyl)-4-cvanopiperidine-4-carboxylic acid; A solution of lithium hydroxide (21.25 ml, 42.50 mmol) in water was added to a stirred solution of 1-tert-butyl 4-ethyl 4-cyanopiperidine-l,4-dicarboxylate (3g, 10.63 mmol), in THF (42.5 ml) at 250C. The resulting mixture was stirred at 25 0C for 18 hours. The reaction mixture was diluted with Et2O (100 mL), and washed with water (50 mL). The aqueous layers were combined and then acidified with citric acid (IN, 50 mL). The product was extracted into DCM. The organic layer was dried over MgSO4, filtered and evaporated to afford crude product l-(tert-butoxycarbonyl)-4-cyanopiperidine-4-carboxylic acid (2.73 g, 101 %) as a yellow liquid. IH NMR (400.13 MHz, DMSO-d6) delta 1.41 (9H, s), 1.78 – 1.85 (2H, m), 2.04 (2H, d) 2.95 (2H, t), 3.96 (2H, d), 13.9 (IH, s), 1016258-66-4

As the paragraph descriping shows that 1016258-66-4 is playing an increasingly important role.

Reference£º
Patent; ASTEX THERAPEUTICS LIMITED; THE INSTITUTE OF CANCER RESEARCH:ROYAL CANCER HOSPITAL; CANCER RESEARCH TECHNOLOGY LIMITED; ASTRAZENECA AB; WO2008/75110; (2008); A1;,
Piperidine – Wikipedia
Piperidine | C5H11N – PubChem

333986-70-2, Methyl 4-(piperidin-4-ylmethyl)benzoate hydrochloride is a piperidines compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

General procedure: Example of General Method C: Preparation of 4-{l-[(S)-4-(2,3-Dihydro-benzo[l,4]dioxin-2-yl)-benzyl]-piperidin-4- ylmethylj-benzoic acid methyl ester A solution of A (100 mg, 0.42 mmol), 4-piperidin-4-ylmethyl-benzoic acid methyl ester hydrochloride (146 mg, 0.54 mmol), sodium cyanoborohydride (52 mg, 0.83 mmol), and TEA (0.08 mL, 0.54 mmol) in THF (5 mL) is treated with 2 drops of acetic acid, and stirred at room temperature for 16 h. The mixture is concentrated, and the residue is purified by flash chromatography eluting with a gradient of 0-10% MeOH in DCM to give the title compound.

333986-70-2, The synthetic route of 333986-70-2 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; BOEHRINGER INGELHEIM INTERNATIONAL GMBH; BRUNETTE, Steven, Richard; ABEYWARDANE, Asitha; BURKE, Michael, J.; KAPADIA, Suresh, R.; KIRRANE, Thomas, Martin, Jr.; NETHERTON, Matthew, Russell; RAZAVI, Hossein; RODRIGUEZ, Sonia; SAHA, Anjan; SIBLEY, Robert; SMITH KEENAN, Lana, Louise; TAKAHASHI, Hidenori; TURNER, Michael, Robert; WU, Jiang-Ping; YOUNG, Erick, Richard, Roush; ZHANG, Qiang; ZHANG, Qing; ZINDELL, Renee, M.; WO2013/134226; (2013); A1;,
Piperidine – Wikipedia
Piperidine | C5H11N – PubChem

158407-04-6, tert-Butyl 4-(bromomethyl)piperidine-1-carboxylate is a piperidines compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

158407-04-6, To a solution of 3-iodo-1H-pyrazolo[3,4-d]pyrimidin-4-amine (3 g, 11.49 mmol, 1.0 equiv) in DMA (30 mL) was added tert-butyl 4-(bromomethyl)piperidine-1-carboxylate (3.36 g, 12.07 mmol, 1.05 equiv) and K2CO3 (4.77 g, 34.48 mmol, 3.0 equiv), then the reaction was stirred at 80 C for 3 h. The reaction mixture was filtered to remove K2CO3 and the filtrate was poured into H2O (200 mL). A solid precipitated was then filtered to give tert- butyl 4-((4-amino-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)piperidine-1-carboxylate (3 g, 57% yield) as light yellow solid. LCMS (ESI) m/z: [M + H] calcd for C16H23IN6O2: 459.10; found 459.1.

The synthetic route of 158407-04-6 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; REVOLUTION MEDICINES, INC.; SEMKO, Christopher Michael; WANG, Gang; BURNETT, G. Leslie; AGGEN, James Bradley; KISS, Gert; CREGG, James Joseph; GLIEDT, Micah James Evans; PITZEN, Jennifer; LEE, Julie Chu-Li; WON, Walter; THOTTUMKARA, Arun P.; GILL, Adrian Liam; (356 pag.)WO2019/212991; (2019); A1;,
Piperidine – Wikipedia
Piperidine | C5H11N – PubChem

203662-51-5, 4-Allyl-1-Boc-4-hydroxypiperidine is a piperidines compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

4 i) 4-Hydroxy-4-oxiranylmethyl-piperidine-l-carboxylic acid tert-butyl esterA solution of 4-allyl-4-hydroxy-piperidine-l-carboxylic acid tert-butyl ester (3.1g, 12.8 mmol, prepared according to J. Comb. Chem. 2002, 4, 125) in DCM and 0.3 M phosphate buffer (pH 8, 150 niL) was treated with mCPBA (3.5 g, 1.1 eq, 70%) and the mixture vigorously stirred at rt overnight. Further 3.5 g of mCPBA were added. After a total of 24 h, the phases were separated, the org. phase dried over MgSO4 and concentrated. CC(hex/EA 2:lto l :lto EA) gave the desired intermediate as colourless oil (0.88 g, 26%).1H NMR (CDCl3) delta: 3.90-3.70 (m, 2H), 3.30-3.10 (m, 3H), 2.83 (dd, ./=4.1 , 4.9 Hz, IH),2.51 (dd, J=2.7, 4.9 Hz, IH), 1.89 (dd, J=3.8, 14.5 Hz, IH), 1.80-1.40 (m, 4H), 1.47 (s,9H)., 203662-51-5

The synthetic route of 203662-51-5 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; ACTELION PHARMACEUTICALS LTD; WO2008/126034; (2008); A2;,
Piperidine – Wikipedia
Piperidine | C5H11N – PubChem

336191-17-4, tert-Butyl 2,8-diazaspiro[4.5]decane-2-carboxylate is a piperidines compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

336191-17-4, EXAMPLE 16; 8-(5-{[(4-Aminobiphenyl-3-yl)amino]carbonyl}pyridin-2-yl)-N-(2-phenylethyl)-2,8-diazaspiro[4.5]decane-2-carboxamide; To a solution of methyl 6-chloronicontinate (200 mg, 1.16 mmol) in DMSO/PhMe (2 mL of a 1:1 solution) was added t-butyl-2,8-diazaspiro[4.5]decane-2-carboxylate (700 mg, 2.91 mmol). The reaction mixture was heated at 85 C. for 6 hours and then diluted with EtOAc (10 mL). The organic layer was washed with NaHCO3 (1¡Á5 mL) and brine (1¡Á5 mL), dried over Na2SO4, and then concentrated. The crude residue was purified by reverse-phase flash chromatography (10-100% MeCN/H2O with 0.05% TFA) to give t-butyl 8-[5-(methoxycarbonyl)pyridin-2-yl]-2,8-diazaspiro[4.5]decane-2-carboxylate: MS (ESI+): cal’d [M+H]+ 376.2, obs’d 376.2.

336191-17-4 tert-Butyl 2,8-diazaspiro[4.5]decane-2-carboxylate 34178604, apiperidines compound, is more and more widely used in various fields.

Reference£º
Patent; Berk, Scott C.; Close, Joshua; Hamblett, Christopher; Heidebrecht, Richard W.; Kattar, Solomon D.; Kliman, Laura T.; Mampreian, Dawn M.; Methot, Joey L.; Miller, Thomas; Sloman, David L.; Stanton, Matthew G.; Tempest, Paul; Zabierek, Anna A.; US2007/117824; (2007); A1;,
Piperidine – Wikipedia
Piperidine | C5H11N – PubChem